The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LI.d

Myocarditis (can be fulminant)

Publications

Bae S, Vaysblat M, Ng J, Beccarino N, Makaryus J, Sarkar K

Durvalumab-Associated Myocarditis Initially Presenting With Sinus Bradycardia Progressing Into Complete Heart Block.

Cureus 2023 Jun;15;e40171 — 2023 Jun — e40171

Maetani T, Hamaguchi T, Nishimura T, Marumo S, Fukui M

Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy.

Internal medicine (Tokyo, Japan) 2021 Aug 24;; — 2021 Aug 24

Cham J, Ng D, Nicholson L

Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.

Journal of medical case reports 2021 May 31;15;278 — 2021 May 31 — 278